Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Jacksonville, Florida 32256


Purpose:

This is an open label, randomized investigation of a proprietary blend of amino acids, called Enterade®, and its effect on irregularity (diarrhea) caused by radiation therapy and/or chemotherapy including TKI*. Subjects will be randomized to receive Enterade® or continue standard of care. Two patients will be enrolled on the treatment arm for each patient on the control arm.


Criteria:

Inclusion Criteria: 1. Patients with any combination of therapies including radiation therapy alone, chemotherapy alone, TKI alone, or any combination are eligible. 2. This includes patients with therapies including Xeloda (capecitabine), Camptosar (irinotecan) or 5-FU (fluorouracil) with cancer. 3. Patients who have been diagnosed with a CID CTCAE toxicity of grade 3 or higher 4. Patients must be at least 18 years of age. 5. ECOG performance status 0-2. 6. Patients must have diarrhea symptoms, judged secondary to the systemic therapy, combined systemic therapy, and/or radiation, and must be requiring loperamide or similar (Imodium®) for symptom management. For the purposes of this study, diarrhea will be defined as three or more loose or liquid stools per day or loose watery stool (greater volume of stool) that occur more frequently than usual and lasting for more than three days. Exclusion Criteria: 1. ECOG performance status 3 or greater. 2. Pregnant and/or breast-feeding women 3. Pre-menopausal subjects as well as subjects with ovarian radiation or concomitant treatment with an LH-RH agonist/antagonist must have a negative pregnancy test and agree to use an adequate method of contraception as recommended by their treating physicians 4. Post-menopausal status is defined either by: 1. age ≥55 years and one year or more of amenorrhea, 2. age <55 years and one year or more of amenorrhea with an estradiol assay <20 pg/mL 3. bilateral oophorectomy 4. CID CTCAE grade 1 or 2 (not requiring Loperamide or similar)


NCT ID:

NCT02381405


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

Jacksonville, Florida 32256
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 23, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.